The role of neuroimaging in the investigation of patients with a first seizure
It is estimated that 10% of the population will have a seizure at some point in their lifetime [1] . A first seizure can be a terrifying experience, and it immediately raises questions about the underlying cause and the likelihood of recurrence. Neuroimaging is used first and foremost to detect an underlying tissue abnormality or structural lesion that can explain the seizure. Prognostication is more challenging, but neuroimaging may show abnormalities that portend further seizures. In some cases, neuroimaging may help to establish a diagnosis of epilepsy [2] . The combination of seizure history, electroencephalography (EEG) and magnetic resonance imaging (MRI) may allow the clinician to diagnose a specific epilepsy syndrome [3, 4] . This, in turn, greatly facilitates patient counseling and early management decisions, such as the initiation of antiepileptic drug therapy or expedited referral for surgical consideration.
There are numerous potential causes for seizures. Some of these causes have no neuroimaging correlate, such as genetically determined primary generalized epilepsy syndromes. Seizures provoked by transient physiological disturbances are usually diagnosed without the aid of neuroimaging, as in the case of febrile convulsions, hypoxia, hypoglycemia and alcohol withdrawal. Here, the role of neuroimaging, when utilized, is primarily to rule out other differential diagnostic considerations. However, seizures may be the presenting symptom of acute conditions that cause specific, detectable tissue changes, such as cerebral venous thrombosis [5] , posterior reversible encephalopathy syndrome [6] , infectious encephalitis [7] and autoimmune encephalitis [8, 9] . Finally, unprovoked seizures may occur in the presence of congenital structural lesions, such as malformations of cortical development and vascular malformations, and acquired structural lesions, such as primary and secondary neoplasms, infarcts and traumatic injuries [10] . In such cases, neuroimaging can be critical in establishing the diagnosis, detecting complications and guiding specific medical or surgical treatments beyond seizure control with antiepileptic drugs.
Neuroimaging is abnormal in nearly one-half of children with new-onset focal seizures, and it provides information about etiology and localization in 15-20%, based on a review by the International League Against Epilepsy (ILAE) Subcommittee for Pediatric Neuroimaging [11] . Neuroimaging research in adults has
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focused largely on chronic epilepsy. However, a recent study of lesions detected by magnetic resonance imaging (MRI) in adults with a first seizure found that a potentially epileptogenic lesion could be identified in 28% of all patients with a seizure and in 53% of patients with a focal onset seizure [12] . In another recent study, MRI showed a cause in 44% of patients who were scanned for ''acute seizure'', half of whom were patients with a first seizure [13] . These studies showed a spectrum of potentially epileptogenic lesions similar to those seen in chronic epilepsy, including neoplasms, vascular malformations, developmental anomalies, gliosis/encephalomalacia from a variety of causes, mesial temporal sclerosis and miscellaneous other lesions [12, 13] . It is not always clear whether a given lesion should be considered epileptogenic or incidental. The epileptogenic potential of neoplasms, vascular malformations, cortical malformations, post-stroke and post-traumatic gliosis/encephalomalacia and mesial temporal sclerosis has long been recognized [10] . Indeed, some developmental neoplasms, such as dysembryoplastic neuroepithelial tumors and gangliogliomas, are so strongly associated with seizures that they have been dubbed ''long-term epilepsy associated tumors'' (LEATs) or ''epileptomas'' [14] . Focal cortical dysplasias (FCDs), whether in isolation or in association with LEATs, are often associated with seizures [15] . However, some neuroimaging findings can pose a dilemma in the setting of a first seizure. For example, while large cortical infarcts can certainly give rise to delayed seizures [16] , the significance of chronic small vessel ischemic changes in the white matter is altogether uncertain. Some authors have classified these findings unequivocally as ''non-epileptogenic'' [12] , while others have considered them a ''potential cause for seizures'' if they were moderate to severe in extent and juxtacortical in location [13] . A recent observation that chronic microvascular lesion load is correlated with dysrhythmic electroencephalography (EEG) recordings supports the hypothesis that these lesions can be epileptogenic [17] . However, more research is needed to evaluate this potential association, given the fact that microvascular lesions are detectable in more than half of all elderly people [18] .
Until recently, neuroimaging was able to expedite the diagnosis of epilepsy after a single unprovoked seizure by detecting a lesion known to be epileptogenic, because such a lesion could confer ''an enduring predisposition to generate epileptic seizures'' [19] . However, the latest definition of epilepsy proposed by the ILAE is more specific and requires ''(1) At least two unprovoked (or reflex) seizures occurring >24 h apart; (2) one unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years; (3) diagnosis of an epilepsy syndrome'' [2] . This definition permits the diagnosis of epilepsy after a single unprovoked seizure if neuroimaging provides evidence of a brain injury secondary to stroke, trauma or infection, because these have a 10-year seizure recurrence risk greater than 60% [20, 21] . Unfortunately, precise data on 10-year recurrence risks are currently lacking for many lesions that are well known to be epileptogenic, such as FCDs. Consequently, the detection of such a lesion can no longer support a diagnosis of epilepsy after a single unprovoked seizure [2] . Research is urgently needed to determine which of the lesions commonly held to be epileptogenic meet the new threshold for diagnosing epilepsy.
First line neuroimaging
Computed tomography (CT) remains the first-line imaging tool in most acute care settings, due to its ability to rapidly rule out an intracranial hemorrhage or a mass requiring urgent neurosurgical attention [22] . Non-contrast CT performed in the emergency department can effectively guide seizure management, particularly when it is performed in the context of a history of predisposing factors, evidence of focal onset or an abnormal neurological exam [23] . Non-contrast CT is perfectly adequate for the detection of epileptogenic foci of gliosis/encephalomalacia secondary to stroke, trauma and infection that account for a significant proportion of unprovoked seizures in adults. Indeed, CT may be the imaging modality of choice for elderly patients, because it is faster and less motion sensitive [24] . CT can contribute to prognosis as well as diagnosis, as adults with abnormal CT findings in the acute care setting are at increased risk of seizure recurrence in the six months following the first seizure [25] . CT remains the predominant neuroimaging tool in some healthcare settings, as seizure management strategies vary significantly around the world for both healthcare culture and resource reasons [26] .
When CT is negative and other imaging modalities are available, the role of neuroimaging shifts toward the identification of a subtler lesion that could account for the seizure. Specifically, MRI becomes essential, because of its superior depiction of brain anatomy and tissue composition. Direct comparisons of CT and MRI have shown that MRI has the higher diagnostic yield for epileptogenic lesions [13, 27] . As noted above, limited data in patients with a first focal seizure or acute seizure suggests a yield around 50% [11] [12] [13] . However, reports of the diagnostic yield of MRI in patients with chronic focal epilepsy have ranged widely from 17 to 91% [27] [28] [29] [30] . What can be unequivocally stated is that many potential MRI findings are still being overlooked, given the high rate of MRI-negativity and evidence from histological examination post-surgery demonstrating pathology that was missed on MRI [31] .
Strategies to improve the diagnostic yield of neuroimaging
Difficulties arise when a patient with an unprovoked focal seizure is not found to have a relevant lesion on MRI and is deemed ''MRI-negative''. Presumably, the elusive epileptogenic lesion is a subtle malformation of cortical development that is either at or below the current limits of MRI resolution. Optimization of conventional MRI technique is the first and most obvious approach to minimizing the proportion of MRI-negative patients. It has long been appreciated that MRI examinations are most likely to yield positive results if they are performed in accordance with dedicated epilepsy protocols and interpreted by experienced diagnosticians with access to detailed clinical and electrophysiological information [29] . Detailed recommendations for MRI epilepsy protocols have been published [32, 33] . The need for thin (<3 mm) T2 and FLAIR images angled parallel and orthogonal to the hippocampal plane, as well as volumetric T1 weighted images with isotropic voxels (<1 mm), has been emphasized [33] . Variations on these protocols, based on universally available, conventional MRI contrasts (T1, T2, FLAIR, gradient recalled echo) and local preferences, remain the cornerstone of epilepsy imaging.
Efforts to improve the detection of epileptogenic lesions by neuroimaging are ongoing. However, most of the work has been done on patients with chronic, medically refractory epilepsy. There is still very limited understanding of early changes during epileptogenesis that could potentially be demonstrated by neuroimaging, and the literature focusing on patients with a first seizure is by no means extensive. This situation is likely the result of the challenges of identifying these individuals and the associated costs of imaging someone who has only experienced one seizure and may not experience another. However, we can turn to studies on patients with medically refractory epilepsy that have served as the proving ground for potential solutions to the problem of MRI-negative epilepsy. A number of innovations have been proposed. In this overview, we will touch on diffusion-based techniques, quantitative MRI acquisition and post-processing techniques, increased MRI field strength, positron emission tomography (PET) and multimodal imaging approaches.
MRI contrast based on the diffusion of water molecules offers a variety of ways to probe tissue microstructure, some of which are only beginning to be explored in epilepsy. For example, lateralization of seizures in temporal lobe epilepsy may be aided by apparent diffusion coefficient mapping [34] , diffusion tensor imaging (DTI) [35, 36] and -most recently -diffusion kurtosis imaging [37] . The detection of focal cortical dysplasias may be improved with surface-based laminar analysis of cortical DTI abnormalities [38] and neurite orientation dispersion and density imaging (NODDI) [39, 40] . The utility of diffusion techniques to detect underlying tissue disorganization has recently been illustrated in patients with malformations of cortical development where there is evidence that the abnormalities may extend far beyond the readily observable lesion [41] . Diffusion data acquisition is within easy reach of most institutions, but the analysis requires post-processing capabilities that are not universally available. Moreover, the utility of the more advanced diffusionbased techniques remains to be established in a larger number of patients.
A number of quantitative MRI acquisition and post-processing techniques have been proposed to increase the diagnostic performance of MRI for the detection of the epileptogenic focus in temporal lobe epilepsy (TLE). For example, hippocampal volumetry can help to lateralize seizures in temporal lobe epilepsy [42] [43] [44] . Similarly, voxel-based morphometry [45] [46] [47] and texture-based analysis [48] can aid in the identification of malformations of cortical development in cases of seizures originating outside the temporal lobe. This may be particularly useful for MRInegative patients with seizures originating in deeper cortical areas, such as orbitofrontal cortex where scalp EEG may not be as accurate [49] . Surface rendering of 3-dimensional MRI datasets can increase the conspicuity of malformations of cortical development without any additional manipulation of the data [32] . Voxel-based volumetric MRI shows promise for the identification of epileptogenic lesions, especially when combined with EEG or MEG [50] . However, our previous work suggests caution in first seizure patients, as MRI lesions and EEG localization may represent different patient populations [51] .
Another quantitative approach is to measure subtle differences in MRI signal. Thus, combined hippocampal volumetry and quantitative FLAIR signal analysis correlates with the histopathological grade of hippocampal sclerosis [52] . T2 relaxometry can help to lateralize seizures in temporal lobe epilepsy [42] [43] [44] , while concurrent use of T1 relaxometry and T2 relaxometry may provide complementary information about temporal lobe pathology [53] . Whole brain T2 mapping has been used to identify neocortical lesions [54] , and voxel-based analysis of FLAIR signal across the brain can identify focal cortical dysplasias in some previously MRInegative patients with refractory focal epilepsy [55] . These nonstandard approaches hold promise, but their utility needs to be validated in further studies, and particularly in first seizure patients, prior to their incorporation into routine clinical imaging. At the present time, the acquisition sequences, post-processing tools and necessary expertise are often not available outside of neuroimaging research centers.
Increased MRI field strength offers increased signal-to-noise and spatial resolution. Thus, high field imaging at 3 T has revealed epileptogenic lesions in some patients who were considered MRInegative at 1.5 T [56, 57] , especially when phased array surface coils were used [58] . Imaging at 3 T has also been shown to resolve very subtle forms of hippocampal sclerosis, such as partial loss of hippocampal striation [59] . More recently, investigators have been exploring the potential benefit of ultra-high field imaging.
Interesting correlations between histopathological findings and ex vivo imaging findings have been reported for hippocampal sclerosis at 7 T [60, 61] and for focal cortical dysplasia at 7 T [62] and 9.4 T [63] . A small number of clinical imaging studies performed to date at 7 T have revealed very subtle morphological alterations in patients with hippocampal sclerosis [64] and have suggested that 7 T is superior to 3 T for the characterization of focal cortical dysplasia [65] and polymicrogyria [66] . Interestingly, metabolic abnormalities demonstrated by preoperative magnetic resonance spectroscopic imaging (MRS) at 7 T were shown to be correlated with postoperative outcome in a small group of patients with focal seizures [67] . It will likely be some time before 7 T scanners become widely available for clinical use.
PET imaging with 18F-fluorodeoxyglucose (FDG) has been used for some time in refractory epilepsy, but could be useful in diagnosis after first seizure. PET can be very helpful in lateralizing temporal lobe seizures in medically refractory, MRI-negative patients [68, 69] . Focal hypometabolism on PET can identify cortical dysplasias, due to reduced mitochondrial complex IV functioning [70] . The diagnostic yield of PET imaging can be increased by combining it with other modalities. For example, PET in combination with magnetoencephalography (MEG) to locate lesions when one test alone is non-localizing or other tests are nonconcordant [71] .
4.
What is the future of neuroimaging in patients with a first seizure?
In the future, clinicians investigating patients with a confirmed first seizure will increasingly adopt neuroimaging strategies developed for the presurgical evaluation of patients with medically refractory epilepsy in an effort to identify epileptogenic lesions earlier and more confidently. This will include more liberal use of high field imaging as this infrastructure becomes more widely available, use of pulse sequences and sophisticated post-processing techniques that are currently considered non-standard, and perhaps the addition of other modalities, such as MEG. It remains to be seen which of these approaches will contribute most to the detection of subtle lesions. Metabolic disturbances may or may not be detectable after a first seizure; hence, the potential value of MRS and PET in this setting will be a subject for future investigation. The role of neuroimaging in the investigation of patients with first seizure will likely evolve beyond the mere detection of epileptogenic lesions. Neuroimaging will likely focus increasingly on explaining seizures in a biological context. This would be in terms of brain network abnormalities, histopathological findings and metabolic changes in individual patients. A greater focus on epileptogenesis and disease evolution could further inform development of new epilepsy treatments that would also be a desirable outcome. This more in depth examination of brain structure following a first seizure may help to predict seizure recurrence with greater accuracy on the individual level. Finally, all of this information will be invaluable in both diagnosis and in imparting a better understanding of their condition to the patient experiencing a first seizure.
